About the Authors

Fruzsina Soltész

fruzsina.x.soltesz@gsk.com (FS); pn254@cam.ac.uk (PN)

FS and JS are joint first authors on this work.

Affiliation Clinical Unit Cambridge, GlaxoSmithKline, Cambridge, United Kingdom

John Suckling

FS and JS are joint first authors on this work.

Affiliation Brain Mapping Unit, Department of Psychiatry, University of Cambridge, United Kingdom

Phil Lawrence

Affiliation Clinical Unit Cambridge, GlaxoSmithKline, Cambridge, United Kingdom

Roger Tait

Affiliation Brain Mapping Unit, Department of Psychiatry, University of Cambridge, United Kingdom

Cinly Ooi

Affiliation Brain Mapping Unit, Department of Psychiatry, University of Cambridge, United Kingdom

Graham Bentley

Affiliation Clinical Unit Cambridge, GlaxoSmithKline, Cambridge, United Kingdom

Chris M. Dodds

Affiliation Department of Psychology, University of Exeter, Exeter, United Kingdom

Sam R. Miller

Affiliation Clinical Unit Cambridge, GlaxoSmithKline, Cambridge, United Kingdom

David R. Wille

Affiliation Clinical Unit Cambridge, GlaxoSmithKline, Cambridge, United Kingdom

Misha Byrne

Affiliation Queensland Brain Institute, University of Queensland, Queensland, Australia

Simon M. McHugh

Affiliation Clinical Unit Cambridge, GlaxoSmithKline, Cambridge, United Kingdom

Mark A. Bellgrove

Affiliation School of Psychology and Psychiatry, Monash University, Melbourne, Australia

Rodney J. Croft

Affiliation Queensland Brain Institute, University of Queensland, Queensland, Australia

Bai Lu

Affiliation Tsinghua University Medical School, Beijing, China

Edward T. Bullmore

Affiliation Brain Mapping Unit, Department of Psychiatry, University of Cambridge, United Kingdom

Pradeep J. Nathan

fruzsina.x.soltesz@gsk.com (FS); pn254@cam.ac.uk (PN)

Affiliations Brain Mapping Unit, Department of Psychiatry, University of Cambridge, United Kingdom, School of Psychology and Psychiatry, Monash University, Melbourne, Australia, New Medicines, UCB Pharma, Brussels, Belgium

Competing Interests

FS, PL, GB, SRM, DRW & SMH are employees of GlaxoSmithKline, whose company funded this study. PJN is an employee of UCB Pharma. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: PJN ETB BL. Performed the experiments: PL GB RT CO JS CMD. Analyzed the data: FS RT CO JS PL GB. Contributed reagents/materials/analysis tools: MAB MB RJC SM. Wrote the paper: FS PJN JS. statistical support and tools: SRM DRW.